

Table 4.4
Counts (Annualized Percentages) of Participants with Self-Reported Outcomes by Age at Enrollment and Race/Ethnicity for OS Participants Who Did Not Report a Prevalent Condition at Baseline

Data as of: February 28, 2017; Events through February 28, 2017

Outcome	Total	Age at Enrollment			
		50-54	55-59	60-69	70-79
Number enrolled	93676	12381	17329	41200	22766
Mean follow-up (months)	172.0	191.6	189.6	173.9	144.7
Hospitalizations					
Ever	64473 (4.80%)	6783 (3.43%)	10739 (3.92%)	29471 (4.93%)	17480 (6.37%)
Two or more	44491 (3.31%)	4083 (2.07%)	6966 (2.54%)	20737 (3.47%)	12705 (4.63%)
Other					
DVT ¹	1840 (0.14%)	147 (0.08%)	243 (0.09%)	902 (0.16%)	548 (0.21%)
Pulmonary embolism	1528 (0.11%)	147 (0.07%)	255 (0.09%)	742 (0.13%)	384 (0.14%)
Diabetes (treated)	11456 (0.88%)	1621 (0.84%)	2304 (0.86%)	5275 (0.91%)	2256 (0.85%)
Gallbladder disease ^{2,3}	5652 (0.95%)	832 (0.96%)	1141 (0.98%)	2534 (0.99%)	1145 (0.85%)
Hysterectomy	4733 (0.35%)	735 (0.37%)	1097 (0.40%)	2143 (0.36%)	758 (0.28%)
Glaucoma ³	8454 (1.26%)	843 (0.88%)	1364 (1.04%)	3886 (1.32%)	2361 (1.56%)
Osteoporosis ³	20669 (3.20%)	2090 (2.21%)	3364 (2.62%)	9502 (3.38%)	5713 (4.01%)
Osteoarthritis ⁴	26415 (3.34%)	4076 (2.85%)	5558 (3.09%)	11662 (3.49%)	5119 (3.88%)
Rheumatoid arthritis ³	4572 (0.68%)	634 (0.67%)	877 (0.68%)	1880 (0.64%)	1181 (0.76%)
Intestinal polyps	21600 (1.77%)	3248 (1.72%)	4770 (1.86%)	9746 (1.82%)	3836 (1.62%)
Lupus	1514 (0.11%)	213 (0.11%)	291 (0.11%)	686 (0.12%)	324 (0.12%)
Kidney stones ^{3,4}	2317 (0.34%)	292 (0.31%)	433 (0.33%)	994 (0.34%)	598 (0.38%)
Cataracts ^{3,4}	27103 (4.66%)	1726 (1.81%)	4088 (3.20%)	14045 (5.47%)	7244 (7.14%)
Hypertension treated w/pills	32999 (3.36%)	4349 (2.63%)	6349 (2.93%)	14833 (3.50%)	7468 (4.23%)
COPD ⁵	3996 (0.83%)	460 (0.67%)	773 (0.82%)	2080 (0.98%)	683 (0.68%)
Macular degeneration ⁶	10493 (1.17%)	719 (0.55%)	1398 (0.77%)	5162 (1.30%)	3214 (1.76%)
Alzheimer's disease ⁶	7513 (0.84%)	306 (0.23%)	679 (0.38%)	3725 (0.94%)	2803 (1.54%)
Parkinson's disease ⁶	1400 (0.16%)	96 (0.07%)	198 (0.11%)	782 (0.20%)	324 (0.18%)

¹ Inpatient DVT only.

² "Gallbladder disease" includes self-reports of both hospitalized and non-hospitalized events.

³ Data not collected for the WHI Extension Studies 2005-2020.

⁴ These outcomes have not been self-reported on all versions of Form 33. The annualized percentages are corrected for the different amounts of follow-up.

⁵ Data only collected during the WHI Extension Study 2010-2020.

⁶ Data only collected during the WHI Extension Studies 2005-2020.

Table 4.4 (continued)
Counts (Annualized Percentages) of Participants with Self-Reported Outcomes by Age at Enrollment and Race/Ethnicity for OS Participants Who Did Not Report a Prevalent Condition at Baseline

Data as of: February 28, 2017; Events through February 28, 2017

Outcomes	Race/Ethnicity					
	American Indian/ Alaskan Native	Asian/Pacific Islander	Black/African American	Hispanic/ Latina	White	Unknown
Number enrolled	421	2671	7635	3609	78016	1324
Mean follow-up (months)	144.9	146.3	139.8	134.9	178.2	156.1
Hospitalizations						
Ever	273 (5.37%)	1185 (3.64%)	4551 (5.12%)	1747 (4.31%)	55890 (4.82%)	827 (4.80%)
Two or more	190 (3.74%)	622 (1.91%)	2860 (3.22%)	1015 (2.50%)	39241 (3.39%)	563 (3.27%)
Other						
DVT ¹	7 (0.15%)	13 (0.04%)	159 (0.18%)	29 (0.07%)	1611 (0.14%)	21 (0.13%)
Pulmonary embolism	4 (0.08%)	11 (0.03%)	104 (0.12%)	18 (0.04%)	1377 (0.12%)	14 (0.08%)
Diabetes (treated)	77 (1.72%)	316 (1.01%)	1244 (1.56%)	520 (1.36%)	9117 (0.81%)	182 (1.10%)
Gallbladder disease ^{2,3}	31 (1.32%)	81 (0.46%)	374 (0.78%)	230 (1.18%)	4860 (0.97%)	76 (0.94%)
Hysterectomy	11 (0.22%)	79 (0.24%)	172 (0.19%)	139 (0.34%)	4262 (0.37%)	70 (0.41%)
Glaucoma ³	45 (1.64%)	253 (1.36%)	987 (1.98%)	308 (1.31%)	6739 (1.18%)	122 (1.32%)
Osteoporosis ³	90 (3.30%)	625 (3.50%)	1069 (2.06%)	735 (3.21%)	17827 (3.29%)	323 (3.64%)
Osteoarthritis ⁴	97 (3.43%)	765 (3.31%)	1851 (3.56%)	1010 (3.80%)	22317 (3.31%)	375 (3.53%)
Rheumatoid arthritis ³	38 (1.39%)	98 (0.53%)	661 (1.33%)	382 (1.65%)	3307 (0.58%)	86 (0.95%)
Intestinal polyps	74 (1.60%)	484 (1.66%)	1579 (1.94%)	641 (1.69%)	18557 (1.77%)	265 (1.72%)
Lupus	10 (0.20%)	25 (0.08%)	142 (0.16%)	72 (0.18%)	1245 (0.11%)	20 (0.12%)
Kidney stones ^{3,4}	17 (0.61%)	40 (0.21%)	263 (0.50%)	125 (0.53%)	1828 (0.32%)	44 (0.47%)
Cataracts ^{3,4}	102 (4.21%)	683 (4.33%)	1937 (4.26%)	894 (4.11%)	23094 (4.73%)	393 (5.02%)
Hypertension treated w/pills	136 (4.07%)	797 (3.43%)	2085 (4.67%)	1165 (3.76%)	28348 (3.27%)	468 (3.77%)
COPD ⁵	18 (0.88%)	39 (0.27%)	212 (0.55%)	81 (0.43%)	3604 (0.90%)	42 (0.63%)
Macular degeneration ⁶	29 (0.74%)	144 (0.56%)	338 (0.48%)	219 (0.65%)	9644 (1.28%)	119 (0.97%)
Alzheimer's disease ⁶	26 (0.67%)	111 (0.43%)	389 (0.56%)	164 (0.49%)	6720 (0.89%)	103 (0.84%)
Parkinson's disease ⁶	6 (0.15%)	17 (0.07%)	70 (0.10%)	29 (0.09%)	1259 (0.17%)	19 (0.15%)

¹ Inpatient DVT only.

² "Gallbladder disease" includes self-reports of both hospitalized and non-hospitalized events.

³ Data not collected for the WHI Extension Studies 2005-2020.

⁴ These outcomes have not been self-reported on all versions of Form 33. The annualized percentages are corrected for the different amounts of follow-up.

⁵ Data only collected during the WHI Extension Study 2010-2020.

⁶ Data only collected during the WHI Extension Studies 2005-2020.